

## Kalbitor® (ecallantide) (Subcutaneous)

Document Number: OHSU HEALTHSERVICES-0167

Last Review Date: 08/05/2025

Date of Origin: 08/27/2013

Dates Reviewed: 04/2014, 09/2014, 03/2015, 06/2015, 09/2015, 12/2015, 03/2016, 06/2016, 09/2016, 12/2016, 03/2017, 06/2017, 09/2017, 12/2017, 03/2018, 06/2018, 10/2018, 10/2019, 03/2020, 10/2020, 10/2021, 10/2022, 10/2023, 08/2024, 08/2025

### I. Length of Authorization

- Initial\*: Prior authorization validity will be provided initially for 12 weeks.
- Renewal\*: Prior authorization validity may be renewed every 12 weeks thereafter.

\*The cumulative amount of medication(s) the patient has on-hand, indicated for the acute treatment of HAE, will be taken into account when authorizing. The authorization will provide a sufficient quantity in order for the patient to have a cumulative amount of HAE medication on-hand in order to treat up to 4 acute attacks per 4 weeks for the duration of the authorization.

### II. Dosing Limits

**Max Units (per dose and over time) [HCPCS Unit]:**

- 240 billable units per 28 days

### III. Initial Approval Criteria <sup>1</sup>

Coverage is provided in the following conditions:

- Patient has had a documented trial with inadequate response, intolerance or contraindication to the use of generic icatibant; **OR**
- Patient is less than 18 years of age

- Patient is at least 12 years of age; **AND**

**Universal Criteria <sup>1,13,18</sup>**

- Must be prescribed by, or in consultation with, a specialist in allergy, immunology, hematology, pulmonology, or medical genetics; **AND**
- Will not be used in combination with another agent indicated for the treatment of acute attacks (i.e., Berinert [C1 esterase inhibitor, human], Firazyr [icatibant], Ruconest [C1 esterase inhibitor,

recombinant]); **NOTE:** Requests for combination duplicate therapy may be appropriate in some situations and will be reviewed on a case-by-case basis; **AND**

- Confirmation the patient is avoiding the following possible triggers for HAE attacks:
  - Estrogen-containing oral contraceptive agents AND hormone replacement therapy; **AND**
  - Antihypertensive agents containing ACE inhibitors or angiotensin II receptor blockers (ARBs); **AND**
  - Dipeptidyl peptidase IV (DPP-IV) inhibitors (e.g., sitagliptin); **AND**
  - Neprilysin inhibitors (e.g., sacubitril); **AND**

#### **Treatment of acute attacks of Hereditary Angioedema (HAE) † Φ <sup>1,13,18,19,21</sup>**

- Patient has a history of moderate to severe cutaneous attacks (without concomitant hives) OR abdominal attacks OR mild to severe airway swelling attacks of HAE (i.e., debilitating cutaneous/gastrointestinal symptoms OR laryngeal/pharyngeal/tongue swelling); **AND**
- Patient has one of the following clinical presentations consistent with a HAE subtype§, which must be confirmed by repeat blood testing (treatment for acute attack should not be delayed for confirmatory testing):

<b><u>HAE I (C1-Inhibitor deficiency) § <sup>13,18,19,21</sup></u></b>
<ul style="list-style-type: none"> <li>• Low C1 inhibitor (C1-INH) antigenic level (C1-INH antigenic level below the lower limit of normal as defined by the laboratory performing the test); <b>AND</b></li> <li>• Low C4 level (C4 below the lower limit of normal as defined by the laboratory performing the test); <b>AND</b></li> <li>• Low C1-INH functional level (C1-INH functional level below the lower limit of normal as defined by the laboratory performing the test); <b>AND</b> <ul style="list-style-type: none"> <li>○ Patient has a family history of HAE; <b>OR</b></li> <li>○ Acquired angioedema has been ruled out (i.e., patient onset of symptoms occurs prior to 30 years of age, normal C1q levels, patient does not have underlying disease such as lymphoma or benign monoclonal gammopathy [MGUS], etc.)</li> </ul> </li> </ul>
<b><u>HAE II (C1-Inhibitor dysfunction) § <sup>18,21</sup></u></b>
<ul style="list-style-type: none"> <li>• Normal to elevated C1-INH antigenic level; <b>AND</b></li> <li>• Low C4 level (C4 below the lower limit of normal as defined by the laboratory performing the test); <b>AND</b></li> <li>• Low C1-INH functional level (C1-INH functional level below the lower limit of normal as defined by the laboratory performing the test)</li> </ul>

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Φ Orphan Drug

## **IV. Renewal Criteria <sup>1</sup>**

Coverage can be renewed based upon the following criteria:

- Patient must continue to meet the universal and other indication-specific relevant criteria identified in section III; **AND**

- Significant improvement in severity and duration of attacks has been achieved and sustained; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include serious hypersensitivity reactions, including anaphylaxis, etc.; **AND**
- The cumulative amount of medication(s) the patient has on-hand, indicated for the acute treatment of HAE, will be taken into account when authorizing. The authorization will provide a sufficient quantity in order for the patient to have a cumulative amount of HAE medication(s) on-hand in order to treat up to 4 acute attacks per 4 weeks for the duration of the authorization.

## V. Dosage/Administration <sup>1</sup>

Indication	Dose
Treatment of Acute Hereditary Angioedema (HAE) attack	Administer 30 mg subcutaneously by a healthcare professional in three 10 mg injections. An additional dose of 30 mg may be administered if the attack persists. Not to exceed a total of two 30 mg doses (60 mg) in 24 hours.  <b>**Note:</b> Kalbitor should <i>ONLY</i> be administered by a healthcare professional.

## VI. Billing Code/Availability Information

### HCPCS Code:

- J1290 – Injection, ecallantide, 1 mg; 1 billable unit = 1 mg

### NDC:

- Kalbitor 10 mg/mL; carton of 3 single-use vials: 47783-0101-xx

## VII. References

1. Kalbitor [package insert]. Lexington, MA; Takeda Pharmaceuticals U.S.A., Inc.; November 2021. Accessed June 2025.
2. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010 Aug 5;363(6):523-31. doi: 10.1056/NEJMoa0905079.
3. Bowen T, Cicardi M, Farkas H, et al. Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. J Allergy Clin Immunol. 2004 Sep;114(3):629-37.
4. Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol. Mar-Apr 2009;19(2):147-151.

5. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. *Allergy Asthma Clin Immunol*. 2010;6(1):24.
6. Craig T, Aygören-Pürsün E, Bork K, et al. WAO Guideline for the Management of Hereditary Angioedema. *World Allergy Organ J*. 2012 Dec;5(12):182-99.
7. Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. *Clin Exp Immunol*. 2005;139(3):379.
8. Betschel S, Badiou J, Binkley K, et al. Canadian hereditary angioedema guideline. *Asthma Clin Immunol*. 2014 Oct 24;10(1):50. doi: 10.1186/1710-1492-10-50.
9. Zuraw BL, Bernstein JA, Lang DM, et al. A focused parameter update: hereditary angioedema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema. *J Allergy Clin Immunol*. 2013 Jun;131(6):1491-3. doi: 10.1016/j.jaci.2013.03.034.
10. Zuraw BL, Banerji A, Bernstein JA, et al. US Hereditary Angioedema Association Medical Advisory Board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. *J Allergy Clin Immunol Pract*. 2013 Sep-Oct;1(5):458-67.
11. Frank MM, Zuraw B, Banerji A, et al. Management of children with Hereditary Angioedema due to C1 Inhibitor deficiency. *Pediatrics*. 2016 Nov. 135(5)
12. Zuraw BL, Bork K, Binkley KE, et al. Hereditary angioedema with normal C1 inhibitor function: Consensus of an international expert panel. *Allergy Asthma Proc*. 2012;33 Suppl 1:145-156.
13. Maurer M, Mager M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. *Allergy*. 2018 Jan 10. doi: 10.1111/all.13384.
14. Lang DM, Aberer W, Bernstein JA, et al. International consensus on hereditary and acquired angioedema. *Ann Allergy Asthma Immunol*. 2012;109:395-402.
15. Wintemberger C, Boccon-Gibod I, Launay D, et al. Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients. *Clin Exp Immunol*. 2014 Oct; 178(1): 112–117.
16. Saule C, Boccon-Gibod I, Fain O, et al. Benefits of progestin contraception in non-allergic angioedema. *Clin Exp Allergy*. 2013 Apr;43(4):475-82.
17. Frank MM, Sergent JS, Kane MA, et al. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema; a double-blind study. *N Engl J Med*. 1972;286:808-812.
18. Betschel S, Badiou J, Binkley K, et al. The International/Canadian Hereditary Angioedema Guideline. *Allergy Asthma Clin Immunol*. 2019; 15: 72. Published online 2019 Nov 25. doi: 10.1186/s13223-019-0376-8.
19. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema. *J Allergy Clin Immunol Pract*. 2021 Jan;9(1):132-150.e3. doi: 10.1016/j.jaip.2020.08.046.

20. Riedl M, Campion M, Horn PT, et al. Response time for ecallantide treatment of acute hereditary angioedema attacks. *Ann Allergy Asthma Immunol.* 2010 Dec;105(6):430-436.e2. doi: 10.1016/j.anai.2010.09.005.
21. Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update. *Allergy.* 2021 Nov 22. doi: 10.1111/all.15214

## Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
D84.1	Defects in the complement system

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
15	KY, OH	CGS Administrators, LLC